

3 August 2016

## 2016/17 Invitation to Tender

PHARMAC is seeking feedback from medical groups, DHB hospital pharmacies and other interested parties on:

- A proposal to tender certain pharmaceuticals for sole supply; and
- The draft process and terms and conditions for the 2016/17 Invitation to Tender (2016/17 Tender).

PHARMAC welcomes all feedback on the draft 2016/17 Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC and would be considered by the PHARMAC Board (or its Delegate, where applicable) prior to making a decision on this proposal.

**ALL RESPONSES ARE DUE BY 5 PM, FRIDAY 2 SEPTEMBER 2016**

Feedback should be provided by submitting an email or letter to the Tender Analysts:

Email: [tender@pharmac.govt.nz](mailto:tender@pharmac.govt.nz)

Letter: Tender Analysts  
PHARMAC  
PO Box 10-254  
Wellington 6143

DDI: Tim Nuthall: (04) 901 3233  
Katie Brownless: (04) 916 7522

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.

### Details of the proposed 2016/17 Tender

In accordance with PHARMAC's objective (to secure, for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided), PHARMAC is consulting on a proposal to tender certain pharmaceuticals for Sole Subsidised Supply to

community pharmacies and/or Hospital Supply Status for supply to DHB hospital pharmacies.

Attached to this letter (as Schedule Two) is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply and/or Hospital Supply Status. Pharmaceuticals are sorted into therapeutic groups and then listed alphabetically in each group by chemical, form and strength. Each pharmaceutical has a 'C' and/or 'H' next to it to indicate whether it is proposed to be tendered for community and/or hospital supply.

In general, the proposed 2016/17 Tender process would be similar to the 2015/16 Tender. A copy of the draft 2016/17 Invitation to Tender is available on our website: [www.pharmac.health.nz](http://www.pharmac.health.nz), or by contacting PHARMAC.

We are seeking feedback on the approach outlined in the following pages, in particular on:

- The proposed tender process and timeline;
- The actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule Two, including the impact of a brand switch on patients and clinical staff; and
- For hospital pharmaceuticals, your views on the appropriate Discretionary Variance (DV) Limit for each pharmaceutical, in the event you consider a 1% DV Limit to be clinically unacceptable.

## **Background**

Since 1997 PHARMAC has been using the strategy of tendering pharmaceuticals for sole supply of pharmaceuticals for a fixed period of time. Regular tendering has proven to be an effective way to encourage competition among suppliers of pharmaceuticals. As in the past, the community and hospital tender processes would be run in unison, however, the pharmaceutical list for community and hospital supply may be different.

## **Key Aspects of Awarding a Tender for Community Pharmaceuticals:**

- For community pharmaceuticals, the tender winning brand would be the only subsidised brand for up to approximately 3 years. The Sole Subsidised Supply period would conclude on 30 June 2020 for all Tenders awarded from the 2016/17 Tender.
- No other brand of the pharmaceutical would be listed (or subsidised) in Section B of the Pharmaceutical Schedule during the Sole Subsidised Supply period.
- Other brands could continue to be marketed, sold and dispensed during the Sole Subsidised Supply Status period, but they would not receive a subsidy.
- Any pharmaceutical that currently carries a manufacturer's surcharge (that is, the additional patient charge above that of the patient co-payment) would become fully subsidised if a tender was awarded for that pharmaceutical.

## **Key Aspects of Awarding a Tender for DHB Hospital Pharmaceuticals:**

- For DHB hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (subject to any allowance for alternative brands under the agreed DV Limits) for up to approximately 3 years. The Hospital

Supply Status period would conclude on 30 June 2020 for all tenders awarded from the 2016/17 Tender.

- No other brand of the pharmaceutical would be listed in Section H of the Pharmaceutical Schedule during the Hospital Supply Status period.

### Key Dates and Timeframes for the 2016/17 Tender:

The proposed timelines for the 2016/17 Tender are as follows:

Date	Event
3 August 2016	Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender.
29 August 2016	Final date for receipt of Alternative Commercial Proposals (ACPs) to tendering by PHARMAC.
2 September 2016	Final date for all consultation to be received.
September 2016	PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC's Factors for Consideration, and enters into provisional contracts with suppliers where appropriate.
September 2016	Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.
September/October 2016	Consultation and decisions on Alternative Commercial Proposals.
Early November 2016	Issuing of the 2016/17 Tender.
15 December 2016	Invitation to Tender closes.
From end of January 2017	Decisions on the first Tender winners announced.

### Contractual obligations for suppliers

A copy of the draft terms and conditions which would form the terms of the 2016/17 Tender contract is available on the PHARMAC website: [www.pharmac.health.nz](http://www.pharmac.health.nz).

### Proposed inclusion of the following provisions in the 2016/17 Invitation to Tender

#### ***Pack size preference***

PHARMAC propose to include a provision in the 2016/17 Invitation to Tender relating to pack size preference.

In summary, where a Tender Item is specified as being available for a Tender Bid for Sole Supply Status, it is the preference of PHARMAC that the pack size for such a Tender Item is a 30 or 90 day pack where the Tender Item is in a tablet or capsule form.

Notwithstanding the preference of PHARMAC for Tender Items to be in pack sizes as specified above, pack sizes may be specified in the comments column in the attached list or you may submit, and PHARMAC will consider and may accept, a Tender Bid for any pack size, including larger pack sizes, following its evaluation of Tender Bids under clause 5 of Schedule Three.

#### ***Matters for evaluation***

PHARMAC propose to include a provision in the 2016/17 Invitation to Tender relating to matters for evaluation.

The Evaluation Committee will evaluate Tender Bids in light of PHARMAC's statutory objective which is "to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided". In doing so the Evaluation Committee will be guided by the Factors for Consideration (Factors) that form part of PHARMAC's then current Operating Policies and Procedures (OPPs), as published on PHARMAC's website ([www.pharmac.govt.nz](http://www.pharmac.govt.nz)), to the extent applicable. More information on the Factors can be found at [www.pharmac.health.nz/factors-for-consideration](http://www.pharmac.health.nz/factors-for-consideration).

The requirement for PHARMAC to pursue its statutory objective means that particular emphasis will be given to those aspects of proposals which demonstrate "health outcomes", and those aspects of proposals which demonstrate the impact on the "funding provided" for pharmaceuticals. Those Factors which relate directly to these aspects will be given the greatest weight by the Evaluation Committee but all Factors are important.

### ***Product identification codes***

PHARMAC propose to include a provision in the 2016/17 Invitation to Tender relating to product identification codes.

The provision would require that, prior to the listing of a new pharmaceutical, the supplier must obtain and notify PHARMAC by submitting a notification of product changes form of the Pharmacode, the GTIN and the CTPP for the Pharmaceutical, no later than the earlier of:

- (a) 10 business days following the Market Notification Date; or
- (b) the 5th day of the month immediately prior to the Start Date.

For the avoidance of doubt, this requirement does not apply in relation to any Pharmaceutical that is a Medical Device.

## Unresolved Tender Bids

PHARMAC would review any unresolved Tender Bids from the 2014/15 Tender and the 2015/16 Tender prior to issuing the 2016/17 Tender, and may close the tender for some of these items, and reissue them as part of the 2016/17 tender. The following Tender Bids remain unresolved, and may potentially be added to the 2016/17 Tender following consultation:

### 2014/15 Invitation to Tender

Chemical Name	Line Item
Atropine sulphate	Inj 600 mcg, 1 ml
Caspofungin	Inj 50 mg
Caspofungin	Inj 70 mg
Celiprolol	Tab 200 mg
Chloramphenicol	Inj 1 g
Clonidine	Inj 150 mcg per ml, 1 ml
Famotidine	Tab 20 mg
Granisetron	Inj 1 mg
Hyoscine N-butylbromide	Inj 20 mg, 1 ml
Lidocaine [Lignocaine] Hydrochloride	Inj 1%, 20 ml
Lidocaine [Lignocaine] Hydrochloride	Inj 1%, 5 ml
Lidocaine [Lignocaine] Hydrochloride	Inj 2%, 20 ml
Lidocaine [Lignocaine] Hydrochloride	Inj 2%, 5 ml
Lidocaine [lignocaine] hydrochloride with adrenaline	Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge
Metformin Hydrochloride	Tab immediate-release 1 g
Naloxone Hydrochloride	Inj 400 mcg per ml, 1 ml
Propranolol	Cap long-acting 60 mg
Urokinase	Inj 10,000 iu
Urokinase	Inj 100,000 iu
Urokinase	Inj 500,000 iu

### 2015/16 Invitation to Tender

Chemical Name	Line Item
Ambrisentan	Tab 10 mg
Ambrisentan	Tab 5 mg
Amiodarone hydrochloride	Inj 50 mg per ml, 3 ml
Amoxicillin clavulanate	Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml
Amoxicillin clavulanate	Grans for oral liq amoxicillin 400 mg with potassium clavulanate 57 mg per 5 ml
Atomoxetine	Cap 10 mg
Atomoxetine	Cap 100 mg
Atomoxetine	Cap 18 mg

Chemical Name	Line Item
Atomoxetine	Cap 25 mg
Atomoxetine	Cap 40 mg
Atomoxetine	Cap 60 mg
Atomoxetine	Cap 80 mg
Azacitidine	Inj 100 mg
Azathioprine	Inj 50 mg
Azathioprine	Tab 25 mg
Azathioprine	Tab 50 mg
Bacillus Calmette-Guérin (BCG) vaccine	Inj containing equal to or greater than 500 million CFU
Baclofen	Inj 2 mg per ml, 5 ml

Chemical Name	Line Item
Cetomacrogol with glycerol	Crn 90% with glycerol 10%, 100 g
Cilazapril	Tab 0.5 mg - 1 mg
Clonazepam	Tab 2 mg
Clonazepam	Tab 500 mcg
Coal tar	Soln BP
Codeine phosphate	Tab 15 mg
Codeine phosphate	Tab 30 mg
Codeine phosphate	Tab 60 mg
Colchicine	Tab 500 mcg
Condom lubricating jelly	<200 ml
Condoms	Female condom
Cytarabine	Inj 1 g
Cytarabine	Inj 2 g
Dimethicone	Lotn 4% head lice suffocant
Dorzolamide hydrochloride	Eye drops 2%
Droperidol	Inj 2.5 mg per ml, 1 ml
Eptifibatide	Inj 0.75 mg per ml, 100 ml
Eptifibatide	Inj 2 mg per ml, 10 ml
Fludarabine phosphate	Inj 50 mg
Hexamine hippurate	Tab 1 g
Ibuprofen	Oral liq 20 mg per ml
Latanoprost with timolol	Eye drops 50 mcg per ml with timolol 0.5%
Levetiracetam	Inj 100 mg per ml, 5 ml
Levetiracetam	Oral liq 100 mg per ml
Levocabastine	Eye drops 0.5 mg per ml
Liquid paraffin with white soft paraffin	Liquid paraffin 50% with white soft paraffin 50% ointment (pack size 100 g or less)
Liquid paraffin with white soft paraffin	Liquid paraffin 50% with white soft paraffin 50% ointment (pack size greater than 100 g)
Mercaptopurine	Tab 50 mg

Chemical Name	Line Item
Mycophenolate mofetil	Cap 250 mg
Mycophenolate mofetil	Tab 500 mg
Nitrofurantoin	Tab 100 mg
Nitrofurantoin	Tab 50 mg
Nitrofurantoin	Tab modified-release 100 mg
Noradrenaline	Inj 1 mg per ml, 4 ml ampoule
Ondansetron	Tab 4 mg
Ondansetron	Tab 8 mg
Pemetrexed	Powder for infusion, 100 mg
Pemetrexed	Powder for infusion, 500 mg
Piperacillin with tazobactam	Inj 4 g with tazobactam 500 mg
Propranolol	Tab 10 mg
Propranolol	Tab 40 mg
Risedronate sodium	Tab 35 mg
Salbutamol	Oral liq 2 mg per 5 ml
Sodium chloride	Inj 0.9%, 10 ml
Sodium chloride	Inj 0.9%, 20 ml
Sodium chloride	Inj 0.9%, 5 ml
Sodium chloride	Soln 0.9% for irrigation, 30 ml
Starch	Powder
Sumatriptan	Tab 100 mg
Sumatriptan	Tab 50 mg
Tamsulosin	Tab 400 mcg
Tolcapone	Tab 100 mg
Voriconazole	Inj 200 mg
Water for Injection	Purified for inj, 10 ml
Water for Injection	Purified for inj, 20 ml
Water for Injection	Purified for inj, 5 ml
Zinc and castor oil	Oint BP (pack size greater than 30 g)

Should any unresolved Tender Bids be declined prior to the release of the 2016/17 Tender, PHARMAC would consider including those pharmaceuticals in the 2016/17 Tender. Currently unresolved Tender Bids have not been included in the draft pharmaceutical list set out in Schedule Two.

### Distribution of Consultation Documents

Although this consultation letter has been widely distributed, should you consider that a particular person, group or agency should receive this letter and/or future tender documents, please feel free to contact PHARMAC or refer it on directly (note, all tender documents and

consultations are also available from our website at [www.pharmac.health.nz/newsconsultation](http://www.pharmac.health.nz/newsconsultation)). We also invite any person or group to contact PHARMAC should you wish to meet to discuss the proposals contained in this consultation letter.

## **Schedule Two: Possible pharmaceuticals for tender for sole supply**

### **Order of pharmaceuticals in this Schedule**

Pharmaceuticals have been listed in groups according to the therapeutic group classification system used in the Pharmaceutical Schedule. Below is a list of these groups, and the corresponding page numbers for your ease of reference. Pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one group.

<b><i>Therapeutic Group</i></b>	<b>Page Numbers</b>
Alimentary Tract and Metabolism	9
Blood and Blood Forming Organs	10
Cardiovascular System	10 – 11
Dermatologicals	11 – 13
Extemporaneously Compounded Preparations & Galenicals	13
Genito-Urinary System	13 – 14
Hormone Preparations – Systemic excluding contraceptives	14
Infections – Agents for Systemic Use	14 – 19
Musculoskeletal System	20
Nervous System	20 – 23
Oncology and Immunosuppressants	23 – 24
Respiratory System and Allergies	24
Sensory Organs	24 – 26
Various	26

### **Information provided for each pharmaceutical**

For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information:

- the current ex-manufacturer subsidy per unit of measure as at 1 July 2016
- the number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2015
- an estimate of the annual community market value at current subsidies (estimated by multiplying the volume of units subsidised in the year ending 30 June 2015 by the relevant listed unit subsidy as at 1 July 2015); and
- comments specifically relating to the Tender of the line item and/or its current listing on the Pharmaceutical Schedule.

### **Explanation of terms, symbols and abbreviations**

Most terms and abbreviations used are self-explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed.

The following table explains the symbols used in the draft pharmaceutical list:

Symbol	Explanation
Underlined	Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 June 2017 unless otherwise stated in the Comments column and a listing of a new brand could only occur after that date.
C	To be tendered for Sole Subsidised Supply Status (community pharmaceuticals).
H	To be tendered for Hospital Supply Status (DHB hospital pharmaceuticals).
PCT	A reference in the Invitation to Tender to allow Pharmaceuticals Cancer Treatments to be listed in Section B of the Pharmaceutical Schedule as part of PHARMAC's Pharmaceutical Cancer Treatments project.
+	PHARMAC has been advised of the existence of a patent.
*	There is no fully funded product available for this line item (in relation to community supply).
@	Additional Stock Pharmaceuticals (ASP) means a Pharmaceutical, marked with an "@", for which the supplier of the successful Tender Bid would be required to hold additional stock.
#	A rebate currently exists.

### Changes to PHARMAC's decision making mechanism

The issues PHARMAC considers when it makes decisions is fundamental in order for PHARMAC to meet its statutory objective, so its important suppliers understand the new Factors for Consideration.

All decisions relating to the 2016/2017 Tender will be made under the Factors for Consideration.

More information on the Factors for Consideration can be found on the PHARMAC website:

<http://www.pharmac.health.nz/medicines/how-medicines-are-funded/factors-for-consideration/>



**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Alimentary Tract and Metabolism**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
<b>Calcium carbonate</b>					
Tab eff 0.875 - 1.75 g (0.5 g - 1 g elemental)	455,940	\$94,380	\$0.2070	C H 1%	Tab eff 1.75 g is currently listed on the Pharmaceutical Schedule. Units shown are for tab eff 1.75 g
<u>Tab 1.25 g (500 mg elemental) - Tab 1.5 g (600 mg elemental)</u>	9,767,931	\$210,206	\$0.0215	C H 1%	Tab 1.25 g is currently listed on the Pharmaceutical Schedule. Units shown are for tab 1.25 g
<b>Carmellose sodium with gelatin and pectin</b>					
Paste	25,268	\$7,677	\$0.3038	C H 1%	
Powder	1,568	\$475	\$0.3029	C H 1%	
<b>Cholecalciferol</b>					
Tab 1.25 mg (50,000 iu)	1,735,766	\$556,834	\$0.3208	C H 1%	
<b>Docusate Sodium</b>					
Tab 50 mg	546,478	\$12,624	\$0.0231	C H 1%	
Tab 120 mg	1,529,568	\$47,875	\$0.0313	C H 1%	
<b>Gliclazide</b>					
Tab 80 mg	25,593,536	\$588,651	\$0.0230	C H 1%	
<b>Iodine supplement</b>					
Tab 150 mcg elemental	8,910,631	\$361,415	\$0.0406	C H 1%	
<b>Iron polymaltose</b>					
Inj 50 mg per ml, 2 ml	40,381	\$122,920	\$3.0440	C H 1%	
<b>Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride</b>					
Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<u>Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg</u>	3,480,687	\$887,575	\$0.2550	C H 1%	
<b>Magnesium sulphate</b>					
Inj 2 mmol per ml, 5ml	12,107	\$15,315	\$1.2650	C H 1%	
<b>Mebeverine hydrochloride</b>					
Tab 135 mg	2,314,813	\$462,963	\$0.2000	C H 1%	
<b>Nystatin</b>					
Oral liq 100,000 u per ml	1,636,128	\$173,839	\$0.1063	C H 1%	
<b>Omeprazole</b>					
Cap 10 mg	5,385,646	\$133,456	\$0.0248	C H 1%	
Cap 20 mg	87,446,947	\$2,827,160	\$0.0323	C H 1%	
Cap 40 mg	25,831,766	\$1,268,598	\$0.0491	C H 1%	
<b>Poloxamer</b>					
Oral drops 10%	281,370	\$35,453	\$0.1260	C H 1%	
<b>Pyridoxine hydrochloride</b>					
Tab 25 mg	584,286	\$13,959	\$0.0239	C H 1%	
Tab 50 mg	1,704,589	\$39,376	\$0.0231	C H 1%	
<b>Ranitidine</b>					
Inj 25 mg per ml, 2 ml	4,967	\$8,692	\$1.7500	C H 1%	
<b>Ranitidine hydrochloride</b>					
Oral liq 150 mg per 10 ml	1,613,078	\$26,454	\$0.0164	C H 1%	
Tab 150 mg	7,863,565	\$161,989	\$0.0206	C H 1%	
Tab 300 mg	2,474,555	\$72,900	\$0.0295	C H 1%	
<b>Rifaximin</b>					
Tab 200 mg - 550 mg	21,900	\$244,420	\$11.1607	C H 1%	Special Authority restrictions may apply. Tab 550 mg is currently listed on the Pharmaceutical Schedule. Units shown are for tab 550 mg

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Alimentary Tract and Metabolism**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Sodium nitroprusside</b> Urinary Ketone Test strip	48,300	\$5,796	\$0.1200	C H 1%	
<b>Thiamine Hydrochloride</b> Tab 50 mg	5,407,646	\$303,910	\$0.0562	C H 1%	
<b>Triamcinolone acetonide</b> <u>0.1% in Dental Paste USP</u>	117,255	\$124,994	\$1.0660	C H 1%	
<b>Ursodeoxycholic acid</b> <u>Cap 250 mg - 300 mg</u>	499,692	\$266,836	\$0.5340	C H 1%	Cap 250 mg is currently listed on the Pharmaceutical Schedule. Units shown are for cap 250 mg. Special Authority restrictions may apply
<b>Zinc sulphate</b> <u>Cap 50 mg elemental</u>	1,189,967	\$130,896	\$0.1100	C H 1%	

**Blood and Blood Forming Organs**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Glucose [Dextrose]</b> <u>Inj 50%, 10 ml</u>	10,285	\$56,568	\$5.5000	C H 1%	
<u>Inj 50%, 90 ml</u>	361	\$5,235	\$14.5000	C H 1%	

**Cardiovascular System**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Amlodipine</b> <u>Tab 2.5 mg</u>	5,741,476	\$126,887	\$0.0221	C H 1%	
<u>Tab 5 mg</u>	14,772,761	\$297,819	\$0.0202	C H 1%	
<u>Tab 10 mg</u>	7,725,949	\$222,816	\$0.0288	C H 1%	
<b>Bendroflumethiazide [Bendrofluazide]</b> <u>Tab 2.5 mg</u>	23,694,660	\$259,693	\$0.0110	C H 1%	
<u>Tab 5 mg</u>	3,090,761	\$55,325	\$0.0179	C H 1%	
<b>Bisoprolol Fumarate</b> <u>Tab 2.5 mg</u>	3,546,502	\$283,720	\$0.0800	C H 1%	PHARMAC reserves the right to implement 3 monthly (stat) dispensing from 1 July 2017 for this product
<u>Tab 5 mg</u>	2,232,240	\$260,435	\$0.1167	C H 1%	PHARMAC reserves the right to implement 3 monthly (stat) dispensing from 1 July 2017 for this product
<u>Tab 10 mg</u>	830,118	\$177,089	\$0.2133	C H 1%	PHARMAC reserves the right to implement 3 monthly (stat) dispensing from 1 July 2017 for this product
<b>Carvedilol</b> <u>Tab 12.5 mg</u>	2,289,689	\$194,624	\$0.0850	C H 1%	
<u>Tab 25 mg</u>	2,734,068	\$287,077	\$0.1050	C H 1%	
<u>Tab 6.25 mg</u>	2,639,122	\$171,543	\$0.0650	C H 1%	
<b>Clonidine</b> <u>TDDS 2.5 mg, 100 mcg per day</u>	53,152	\$170,086	\$3.2000	C H 1%	
<u>TDDS 5 mg, 200 mcg per day</u>	20,039	\$90,376	\$4.5100	C H 1%	
<u>TDDS 7.5 mg, 300 mcg per day</u>	14,867	\$84,296	\$5.6700	C H 1%	
<b>Doxazosin mesylate</b> <u>Tab 2 mg</u>	14,503,481	\$195,797	\$0.0135	C H 1%	
<u>Tab 4 mg</u>	11,171,780	\$216,062	\$0.0193	C H 1%	
<b>Ephedrine</b> Inj 30 mg per ml, 1ml				H 1%	
<b>Ezetimibe</b> <u>Tab 10 mg</u>	6,181,785	\$690,320	\$0.1117	C H 1%	Special Authority restrictions may apply

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Cardiovascular System**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Ezetimibe with simvastatin</b>						
<u>Tab 10 mg with simvastatin 10 mg</u>	58,380	\$10,022	\$0.1717 #	C H	1%	Special Authority restrictions may apply
<u>Tab 10 mg with simvastatin 20 mg</u>	87,596	\$17,957	\$0.2050 #	C H	1%	Special Authority restrictions may apply
<u>Tab 10 mg with simvastatin 40 mg</u>	220,568	\$52,568	\$0.2383 #	C H	1%	Special Authority restrictions may apply
<u>Tab 10 mg with simvastatin 80 mg</u>	177,506	\$48,223	\$0.2717 #	C H	1%	Special Authority restrictions may apply
<b>Glyceryl trinitrate</b>						
<u>TDDS 25 mg, 5 mg per day</u>	88,377	\$46,339	\$0.5243	C H	1%	
<u>TDDS 50 mg, 10 mg per day</u>	40,154	\$24,922	\$0.6207	C H	1%	
<b>Isosorbide mononitrate</b>						
<u>Tab 20 mg</u>	567,781	\$97,090	\$0.1710	C H	1%	
Tab long-acting 60 mg	8,464,073	\$798,416	\$0.0943	C H	1%	
<b>Losartan</b>						
<u>Tab 12.5 mg</u>	2,311,295	\$42,643	\$0.0185	C H	1%	
<u>Tab 25 mg</u>	3,838,550	\$86,828	\$0.0226	C H	1%	
<u>Tab 50 mg</u>	6,584,763	\$176,406	\$0.0268	C H	1%	
<u>Tab 100 mg</u>	3,105,142	\$96,104	\$0.0310	C H	1%	
<b>Losartan with hydrochlorothiazide</b>						
<u>Tab 50 mg with hydrochlorothiazide 12.5 mg</u>	3,276,254	\$238,085	\$0.0727	C H	1%	
<b>Nicotinic acid</b>						
<u>Tab 50 mg</u>	864,020	\$34,215	\$0.0396	C H	1%	
<u>Tab 500 mg</u>	725,035	\$125,939	\$0.1737	C H	1%	
<b>Nifedipine</b>						
Tab long-acting 10 mg	697,939	\$206,122	\$0.2953	C H	1%	
Tab long-acting 20 mg	636,729	\$61,062	\$0.0959	C H	1%	
Cap 5 mg				H	1%	
<u>Tab long-acting 30 mg</u>	516,262	\$64,533	\$0.1250	C H	1%	
<u>Tab long-acting 60 mg</u>	191,623	\$36,728	\$0.1917	C H	1%	
<b>Perindopril</b>						
<u>Tab 2 mg</u>	304,555	\$38,069	\$0.1250	C H	1%	
<u>Tab 4 mg</u>	684,720	\$109,555	\$0.1600	C H	1%	
<b>Pravastatin</b>						
<u>Tab 20 mg</u>	2,733,241	\$314,323	\$0.1150	C H	1%	
<u>Tab 40 mg</u>	1,264,490	\$268,072	\$0.2120	C H	1%	
<b>Simvastatin</b>						
<u>Tab 10 mg</u>	5,429,329	\$57,334	\$0.0106	C H	1%	
<u>Tab 20 mg</u>	25,732,837	\$460,360	\$0.0179	C H	1%	
<u>Tab 40 mg</u>	23,387,379	\$735,299	\$0.0314	C H	1%	
<u>Tab 80 mg</u>	1,738,220	\$152,772	\$0.0879	C H	1%	
<b>Verapamil hydrochloride</b>						
Tab 40 mg	248,467	\$17,418	\$0.0701	C H	1%	
Tab 80 mg	90,928	\$10,675	\$0.1174	C H	1%	
Tab long-acting 120 mg	1,790,895	\$108,886	\$0.0608	C H	1%	
Tab long-acting 240 mg	1,161,497	\$116,150	\$0.1000	C H	1%	

**Dermatologicals**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Acitretin</b>						
<u>Cap 10 mg</u>	435,848	\$129,739	\$0.2977	C H	1%	Special Authority restrictions may apply
<u>Cap 25 mg</u>	96,391	\$66,445	\$0.6893	C H	1%	Special Authority restrictions may apply
<b>Adapalene</b>						
Crm 0.1%	279,510	\$213,266	\$0.7630 #	C H	1%	
Gel 0.1%	491,700	\$375,167	\$0.7630 #	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Dermatologicals**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
<b>Benzoyl peroxide</b> Soln 5%				H 1%	
<b>Betamethasone valerate with clioquinol</b> Crn 0.1% with clioquinol 3%	77,460	\$18,023	\$0.2327	C H 1%	There may be a preference for a pack size of 50 g or less. There may be a preference for tubes
<b>Brimonidine</b> Gel 0.5%				C H 1%	Not currently listed in the Pharmaceutical Schedule.
<b>Cetrimide</b> Solution 20% (pack size equal to or less than 100 ml)				C H 1%	Not currently listed in the Pharmaceutical Schedule.
<b>Clotrimazole</b> <u>Crn 1%</u>	4,045,380	\$105,180	\$0.0260	C H 1%	
<b>Coal tar</b> Shampoo 4% (pack size equal to or less than 100 ml)				C H 1%	Not currently listed in the Pharmaceutical Schedule
<b>Econazole nitrate</b> Crn 1% (pack size 30 g or less)	28,180	\$1,409	\$0.0500	C H 1%	
<b>Emulsifying ointment</b> Oint BP (pack size 200 g or less) <u>Oint BP (pack size greater than 200 g)</u>	50,830,848	\$277,536	\$0.0055	C H 1%	
<b>Hydrocortisone</b> <u>Powder</u>	77,153	\$183,624	\$2.3800	C H 1%	
<b>Hydrocortisone Butyrate</b> Oint 0.1% (pack size greater than 30 g)	2,862,100	\$196,054	\$0.0685	C H 1%	
<b>Hydrocortisone with wool fat and mineral oil</b> <u>Lotn 1% with wool fat hydrous 3% and mineral oil</u>	11,418,205	\$482,762	\$0.0423	C H 1%	
<b>Imiquimod</b> <u>Crn 5%</u>	300,608	\$450,410	\$1.4983	C H 1%	
<b>Isotretinoin</b> Cap 5 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions.
<b>Ivermectin</b> Cream 1%				C H 1%	Not currently listed in the Pharmaceutical Schedule.
<b>Ketoconazole</b> <u>Shampoo 2%</u>	5,215,400	\$155,940	\$0.0299	C H 1%	
<b>Methylprednisolone aceponate</b> Crn 0.1%  Oint 0.1%	558,315  359,175	\$184,244  \$118,528	\$0.3300  \$0.3300	C H 1%  C H 1%	There may be a preference for pack size of 30 g or less. There may be a preference for tubes  There may be a preference for pack size of 30 g or less. There may be a preference for tubes
<b>Miconazole nitrate</b> <u>Crn 2% (15 g - 20 g pack)</u>	2,374,170	\$87,061	\$0.0367	C H 1%	
<b>Paraffin (current access)</b> White soft - 2,500 g  White soft - 500 g			\$0.0081  \$0.0072 *	C H 1%  C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access  PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Dermatologicals**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Paraffin (widened access)</b>					
White soft - 2,500 g				C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access
White soft - 500 g				C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access
<b>Permethrin</b>					
<u>Crn 5%</u>	1,409,370	\$197,312	\$0.1400	C H 1%	
<u>Lotion 5%</u>	1,980,990	\$210,639	\$0.1063	C H 1%	
<b>Silver Sulphadiazine</b>					
Crn 1%, 50 g	537,400	\$132,200	\$0.2460	C H 1%	
<b>Tar with triethanolamine lauryl sulphate and fluorescein</b>					
<u>Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium</u>	37,684,854	\$253,242	\$0.0067	C H 1%	
<b>Triamcinolone acetonide</b>					
<u>Crn 0.02%</u>	1,660,100	\$104,586	\$0.0630	C H 1%	
<u>Oint 0.02%</u>	904,000	\$57,404	\$0.0635	C H 1%	
<b>Zinc</b>					
Paste (pack size equal to or less than 50 g)				C H 1%	Not currently listed in the Pharmaceutical Schedule.
<b>Zinc and castor Oil</b>					
Oint BP (pack size 30 g or less)				H 1%	

**Extemporaneously Compounded Preparations & Galenicals**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Glycerol</b>					
<u>Liq BP</u>	1,661,665	\$12,330	\$0.0074	C H 1%	There may be a preference for pack size < 500 mL

**Genito Urinary System**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Cyproterone acetate with ethinyloestradiol</b>					
<u>Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets</u>	10,887,268	\$347,304	\$0.0319	C H 1%	
<b>Ergometrine maleate</b>					
<u>Inj 500 mcg per ml, 1 ml</u>	1,726	\$32,690	\$18.9400	C H 1%	
<b>Finasteride</b>					
<u>Tab 5 mg</u>	3,295,497	\$228,477	\$0.0693	C H 1%	Preference for a blister pack. May be subject to Special Authority restrictions
<b>Levonorgestrel</b>					
<u>Subdermal implant</u>	11,717	\$1,565,977	\$133.6500 #	C H 1%	For contraception. Confidential rebate applies. Sole Supply protection until 31/12/17
<b>Miconazole nitrate</b>					
<u>Vaginal crm 2% with applicator</u>	454,600	\$44,892	\$0.0988	C H 1%	Single use applicators preferred
<b>Nystatin</b>					
Vaginal crm 100,000 u per 5 g with applicator(s)	148,425	\$9,321	\$0.0628	C H 1%	Units and unit subsidy expressed as 'per g'
<b>Oestriol</b>					
Crn 1 mg per g with applicator(s)	2,489,445	\$1,045,567	\$0.4200	C H 1%	Applicator(s) should be multiple use and a measured dose
Pessaries 500 mcg	351,513	\$153,024	\$0.4353	C H 1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Genito Urinary System**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Pregnancy tests - HCG urine</b>					
Pregnancy test - HCG urine - Dipstick				C	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all of the tenders for pregnancy tests - HCG urine
<u>Pregnancy tests - HCG urine - Cassette</u>	450,720	\$198,317	\$0.4400	C	PHARMAC reserves the right to award one, some or all of the tenders for pregnancy tests - HCG urine
Pregnancy tests - HCG urine - Midstream				C	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all of the tenders for pregnancy tests - HCG urine
<b>Sodium Citro-Tartrate</b>					
<u>Grans effervescent 4 g sachets</u>	2,014,537	\$210,801	\$0.1046	C H 1%	

**Hormone Preparations - Systemic Excluding Contraceptive Hormones**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Calcitonin</b>					
<u>Inj 100 iu per ml, 1 ml</u>	593	\$14,351	\$24.2000	C H 1%	
<b>Desmopressin</b>					
<u>Nasal spray 10 mcg per dose</u>	82,986	\$317,421	\$3.8250	C H 1%	
<b>Prednisone</b>					
Tab 1 mg	11,280,568	\$240,953	\$0.0214	C H 1%	
Tab 2.5 mg	2,068,985	\$50,028	\$0.0242	C H 1%	
Tab 20 mg	6,106,273	\$354,530	\$0.0581	C H 1%	
Tab 5 mg	12,559,146	\$278,562	\$0.0222	C H 1%	
<b>Testosterone</b>					
Transdermal patch 2.5 mg	161,421	\$215,227	\$1.3333	C H 1%	Special Authority restrictions may apply
<b>Testosterone cypionate</b>					
<u>Inj long-acting 100 mg per ml, 10 ml</u>	1,394	\$106,641	\$76.5000	C H 1%	
<b>Triamcinolone acetonide</b>					
<u>Inj 10 mg per ml, 1 ml</u>	4,338	\$18,046	\$4.1600	C H 1%	PHARMAC reserves its right to list a preservative free product for a restricted market
<u>Inj 40 mg per ml, 1 ml</u>	75,295	\$769,515	\$10.2200	C H 1%	PHARMAC reserves its right to list a preservative free product for a restricted market

**Infections**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Abacavir sulphate</b>					
<u>Oral liq 20 mg per ml</u>	2,880	\$3,076	\$1.0680	C H 1%	
<u>Tab 300 mg</u>	28,732	\$109,661	\$3.8167	C H 1%	
<b>Albendazole</b>					
Tab 200 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions
Tab 400 mg	1,069	\$8,360	\$7.8200	C H 1%	Special Authority restrictions may apply
<b>Amikacin</b>					
Inj 250 mg per ml, 2 ml				H 1%	Preference for syringes
<b>Amoxicillin</b>					
Grans for oral liq 125 mg per 5 ml	27,712,090	\$243,866	\$0.0088	C H 1%	More than one brand currently listed in Section B of the Pharmaceutical Schedule. Unit subsidy shown is the average unit subsidy of the products listed in 2015 FYR

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Infections**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Amoxicillin</b>					
Grans for oral liq 250 mg per 5 ml	32,430,667	\$335,982	\$0.0104	C H 1%	More than one brand currently listed in Section B of the Pharmaceutical Schedule. Unit subsidy shown is the average unit subsidy of the products listed in 2015 FYR
<u>Inj 250 mg</u>	356	\$380	\$1.0670	C H 1%	
<u>Inj 500 mg</u>	1,222	\$1,517	\$1.2410	C H 1%	
<u>Inj 1 g</u>	6,610	\$11,429	\$1.7290	C H 1%	
<b>Amoxicillin clavulanate</b>					
<u>Tab amoxycillin 500 mg with potassium clavulanate 125 mg</u>	16,059,781	\$1,565,829	\$0.0975	@ C H 1%	
<b>Amphotericin B</b>					
Inj 50 mg (non-liposomal)				H 1%	
<b>Artemether with lumefantrine</b>					
Tab 20 mg with lumefantrine 120 mg				H 1%	
<b>Artesunate</b>					
Inj 60 mg				H 1%	
<b>Atazanavir Sulphate</b>					
Cap 150 mg	170,050	\$1,610,770	\$9.4723	C H 1%	Special Authority restrictions may apply
Cap 200 mg	36,354	\$459,145	\$12.6298	C H 1%	Special Authority restrictions may apply
<b>Atovaquone with proguanil hydrochloride</b>					
Tab 250 mg with proguanil hydrochloride 100 mg				H 1%	
Tab 62.5mg with proguanil hydrochloride 25 mg (Paediatric)				H 1%	
<b>Aztreonam</b>					
Inj 1 g				H 1%	
<b>Benzylpenicillin sodium [Penicillin G]</b>					
<u>Inj 600 mg</u>	6,704	\$6,939	\$1.0350	C H 1%	
<b>Cefazolin sodium</b>					
<u>Inj 500 mg</u>	201	\$160	\$0.7980	C H 1%	
<u>Inj 1 g</u>	18,448	\$12,471	\$0.6760	C H 1%	
<b>Cefotaxime</b>					
Inj 500 mg				H 1%	
Inj 1 g				H 1%	
<b>Ceftazidime</b>					
Inj 500 mg				H 1%	
Inj 1 g				H 1%	
Inj 2 g				H 1%	
<b>Cefuroxime</b>					
Oral suspension 25 mg per ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions
Oral suspension 50 mg per ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions
<b>Cefuroxime sodium</b>					
Inj 750 mg				H 1%	
Inj 1.5 g				H 1%	
<b>Chloroquine phosphate</b>					
Tab 250 mg				H 1%	
<b>Cidofovir</b>					
Inj 75 mg per ml, 5 ml				H 1%	
<b>Ciprofloxacin</b>					
<u>Tab 250 mg</u>	245,441	\$15,340	\$0.0625	C H 1%	

sole supply

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Infections**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
<b>Ciprofloxacin</b>					
<u>Tab 500 mg</u>	1,357,159	\$96,942	\$0.0714	C H 1%	
<u>Tab 750 mg</u>	28,413	\$3,805	\$0.1339	C H 1%	
<b>Clarithromycin</b>					
Inj 500 mg				H 1%	
<u>Tab 250 mg</u>	69,788	\$19,840	\$0.2843	C H 1%	Special Authority restrictions may apply
<u>Tab 500 mg</u>				H 1%	
<b>Clofazimine</b>					
Cap 50 mg	6,489	\$28,681	\$4.4200	C H 1%	
<b>Cycloserine</b>					
Cap 250 mg	2,989	\$38,693	\$12.9450	C H 1%	
<b>Dapsone</b>					
<u>Tab 100 mg</u>	36,347	\$39,981	\$1.1000	C H 1%	
<u>Tab 25 mg</u>	74,057	\$70,354	\$0.9500	C H 1%	
<b>Demeclocycline</b>					
Cap 150 mg				H 1%	
Cap 300 mg				H 1%	
<b>Doxycycline hydrochloride</b>					
Tab 20 - 40 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions
Tab 50 mg	476,359	\$46,050	\$0.0967	C H 1%	
<u>Tab 100 mg</u>	10,794,574	\$291,453	\$0.0270	C H 1%	
<b>Flucloxacillin sodium</b>					
<u>Inj 250 mg</u>	44	\$39	\$0.8800	C H 1%	
<u>Inj 500 mg</u>	479	\$441	\$0.9200	C H 1%	
<u>Inj 1 g</u>	6,349	\$7,365	\$1.1600	C H 1%	
<b>Fluconazole</b>					
<u>Cap 50 mg</u>	119,580	\$14,904	\$0.1246	C H 1%	
<u>Cap 150 mg</u>	60,007	\$42,605	\$0.7100	C H 1%	
<u>Cap 200 mg</u>	64,705	\$22,392	\$0.3461	C H 1%	
<b>Flucytosine</b>					
Cap 500 mg				H 1%	
<b>Foscarnet sodium</b>					
Inj 24 mg per ml, 250 ml				H 1%	
<b>Fosfomycin</b>					
Powder for oral solution, 3 g sachet				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions
<b>Fusidic acid</b>					
Tab 250 mg	23,380	\$67,218	\$2.8750	C H 1%	
<b>Imipenem with cilastatin</b>					
Inj 500 mg with cilastatin 500 mg				H 1%	
<b>Itraconazole</b>					
Oral liq 10 mg per ml	3,300	\$3,120	\$0.9453	C H 1%	Special Authority restrictions may apply
<b>Lamivudine</b>					
<u>Oral liq 5 mg per ml</u>	12,180	\$13,703	\$1.1250	C H 1%	Special Authority restrictions may apply
<u>Oral liq 10 mg per ml</u>	3,120	\$1,332	\$0.4271	C H 1%	Special Authority restrictions may apply
<u>Tab 100 mg</u>	184,402	\$39,515	\$0.2143	C H 1%	Special Authority restrictions may apply
<u>Tab 150 mg</u>	9,368	\$8,197	\$0.8750	C H 1%	Special Authority restrictions may apply
<b>Mebendazole</b>					
Oral liq 100 mg per 5 ml	30,787	\$4,474	\$0.1453	C H 1%	Units and unit subsidy expressed as 'per ml'
Tab 100 mg	45,561	\$45,922	\$1.0079	C H 1%	



**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

Infections						
Chemical Name	Units	Cost	Unit Subsidy	DV	Limit	Comments
Line Item						
<b>Mefloquine hydrochloride</b>						
Tab 250 mg				H	1%	
<b>Meropenem</b>						
Inj 500 mg				H	1%	
Inj 1 g				H	1%	
<b>Metronidazole</b>						
Inj 5 mg per ml, 100ml				H	1%	
<b>Minocycline hydrochloride</b>						
Cap 100 mg	185,152	\$35,771	\$0.1932	C H	1%	PHARMAC may choose to accept one or both presentations of minocycline capsules/tablets
Tab 50 mg	586,191	\$56,567	\$0.0965	C H	1%	PHARMAC may choose to accept one or both presentations of minocycline capsules/tablets. Special Authority restrictions may apply
<b>Nitazoxanide</b>						
Oral liq 100 mg per 5 ml				H	1%	
<b>Nitrofurantoin</b>						
Tab modified-release 50 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Norfloxacin</b>						
Tab 400 mg	200,997	\$27,135	\$0.1350	C H	1%	
<b>Pegylated interferon alpha-2a</b>						
<u>Inj 135 mcg prefilled syringe</u>			\$362.0000	C H	1%	PHARMAC reserves the right to award one, some or all presentations across the range of pegylated interferon. May be subject to Special Authority restrictions.
<u>Inj 135 mcg prefilled syringe x 4 with ribavirin tab 200 mg x 168</u>			\$1,975.0000	C H	1%	PHARMAC reserves the right to award one, some or all presentations across the range of pegylated interferon. May be subject to Special Authority restrictions.
<u>Inj 180 mcg prefilled syringe</u>	272	\$61,200	\$225.0000 #	C H	1%	PHARMAC reserves the right to award one, some or all presentations across the range of pegylated interferon. May be subject to Special Authority restrictions.
<u>Inj 180 mcg prefilled syringe x 4 with ribavirin tab 200 mg x 168</u>	815	\$1,051,350	\$1,290.0000 #	C H	1%	PHARMAC reserves the right to award one, some or all presentations across the range of pegylated interferon. May be subject to Special Authority restrictions.
<b>Pegylated interferon alpha-2b</b>						
Inj 100 mcg				C H	1%	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all presentations across the range of pegylated interferon. May be subject to Special Authority restrictions.
inj 120 mcg				C H	1%	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all presentations across the range of pegylated interferon. May be subject to Special Authority restrictions.
Inj 150 mcg				C H	1%	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all presentations across the range of pegylated interferon. May be subject to Special Authority restrictions.
Inj 50 mcg				C H	1%	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all presentations across the range of pegylated interferon. May be subject to Special Authority restrictions.

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

Infections						
Chemical Name	Units	Cost	Unit Subsidy	DV	Limit	Comments
Line Item						
<b>Pegylated interferon alpha-2b</b>						
Inj 80 mcg				C H	1%	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all presentations across the range of pegylated interferon. May be subject to Special Authority restrictions.
<b>Pegylated interferon alpha-2b with ribavirin</b>						
Inj 100 mcg x 4 with ribavirin cap 200 mg x 112				C H	1%	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all presentations across the range of pegylated interferon. May be subject to Special Authority restrictions.
Inj 120 mcg x 4 with ribavirin cap 200 mg x 140				C H	1%	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all presentations across the range of pegylated interferon. May be subject to Special Authority restrictions.
Inj 150 mcg x 4 with ribavirin cap 200 mg x 168				C H	1%	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all presentations across the range of pegylated interferon. May be subject to Special Authority restrictions.
Inj 50 mcg x 4 with ribavirin cap 200 mg x 112				C H	1%	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all presentations across the range of pegylated interferon. May be subject to Special Authority restrictions.
Inj 80 mcg x 4 with ribavirin cap 200 mg x 168				C H	1%	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all presentations across the range of pegylated interferon. May be subject to Special Authority restrictions.
<b>Pentamidine isethionate</b>						
Inj 300 mg				H	1%	
<b>Pivmecillinam</b>						
Tab 200 mg				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions
<b>Praziquantel</b>						
Tab 600 mg	862	\$7,327	\$8.5000	C H	1%	
<b>Primaquine phosphate</b>						
Tab 7.5 - 15 mg	1,116	\$2,332	\$2.0893	C H	1%	Tab 7.5 mg tablet is currently listed in Section B of the Pharmaceutical Schedule. Units shown are for 7.5 mg tab. Special Authority restrictions may apply
<b>Procaine penicillin</b>						
Inj 1.5 mega u	1,474	\$36,408	\$24.7000	C H	1%	
<b>Pyrazinamide</b>						
Tab 500 mg	81,750	\$48,232	\$0.5900	C H	1%	
<b>Pyrimethamine</b>						
Tab 25 mg	1,306	\$965	\$0.7390	C H	1%	Special Authority restrictions may apply
<b>Quinine dihydrochloride</b>						
Inj 600 mg				H	1%	
<b>Quinine sulphate</b>						
Tab 300 mg	1,051,258	\$130,167	\$0.1238	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

Infections						
Chemical Name	Units	Cost	Unit Subsidy	DV	Limit	Comments
Line Item						
<b>Ribavirin</b>						
Tab 200 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions. PHARMAC may choose to accept one, some or all presentations of ribavirin tablets.
Tab 400 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions. PHARMAC may choose to accept one, some or all presentations of ribavirin tablets.
Tab 600 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions. PHARMAC may choose to accept one, some or all presentations of ribavirin tablets.
<b>Rifampicin</b>						
Cap 150 mg	57,637	\$32,133	\$0.5575	C H	1%	
Cap 300 mg	116,530	\$135,466	\$1.1625	C H	1%	
Inj 600 mg				H	1%	
Oral liq 100 mg per 5 ml	98,154	\$19,631	\$0.2000	C H	1%	
Tab 600 mg	4,592	\$16,638	\$3.6233	C	1%	Not currently listed in Section B of the Pharmaceutical Schedule
<b>Ritonavir</b>						
Tab 100 mg	163,460	\$235,982	\$1.4437	C H	1%	
<b>Spiramycin</b>						
Tab 500 mg				H	1%	
<b>Streptomycin sulphate</b>						
Inj 400 mg per ml, 2.5 ml				H	1%	
<b>Sulfadiazine Sodium</b>						
Tab 500 mg	3,620	\$18,617	\$5.1429	C H	1%	
<b>Terbinafine</b>						
Tab 250 mg	2,130,781	\$228,292	\$0.1071	C H	1%	
<b>Ticarcillin with clavulanic acid</b>						
Inj 3g with clavulanic acid 0.1 mg vial				H	1%	
<b>Tigecycline</b>						
Inj 50 mg				H	1%	
<b>Tobramycin</b>						
Powder BP				H	1%	
Inj 100 mg per ml, 5 ml				H	1%	
<b>Trimethoprim</b>						
Oral liq				H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 100 mg				H	1%	
<b>Trimethoprim with sulphamethoxazole [Co-trimoxazole]</b>						
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml				H	1%	
Tab trimethoprim 80 mg and sulphamethoxazole 400 mg				H	1%	
<b>Vancomycin hydrochloride</b>						
Inj 500 mg	5,515	\$14,560	\$2.6400	C H	1%	
<b>Zidovudine [AZT]</b>						
Inj 10 mg per ml, 20 ml vial				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
<b>Zidovudine [AZT] with lamivudine</b>						
Tab 300 mg with lamivudine 150 mg	77,086	\$56,529	\$0.7333	C H	1%	Special Authority restrictions may apply

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Musculoskeletal System**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Allopurinol</b>					
Tab 100 mg	22,426,546	\$338,865	\$0.0151	C H 1%	A scored tablet is preferred
Tab 300 mg	15,786,424	\$502,324	\$0.0318	C H 1%	A scored tablet is preferred
<b>Baclofen</b>					
Tab 10 mg	4,595,482	\$176,926	\$0.0385	C H 1%	
<b>Diclofenac sodium</b>					
Inj 25 mg per ml, 3 ml	26,032	\$68,724	\$2.6400	C H 1%	
Suppos 12.5 mg	7,110	\$1,450	\$0.2040	C H 1%	
Suppos 25 mg	6,527	\$1,593	\$0.2440	C H 1%	
Suppos 50 mg	74,024	\$31,238	\$0.4220	C H 1%	
Suppos 100 mg	113,130	\$79,191	\$0.7000	C H 1%	
<b>Ibuprofen</b>					
Inj 10 mg per ml, 2 ml				H 1%	
Inj 5 mg per ml, 2 ml				H 1%	
Tab 200 mg	57,119,244	\$539,777	\$0.0095	C H 1%	
<b>Neostigmine metisulfate</b>					
Inj 2.5 mg per ml, 1 ml	14,705	\$28,822	\$1.9600	C H 1%	
<b>Pamidronate disodium</b>					
Inj 3 mg per ml, 10 ml	569	\$3,869	\$6.8000	C H 1%	
Inj 6 mg per ml, 10 ml	198	\$2,614	\$13.2000	C H 1%	
Inj 9 mg per ml, 10 ml	326	\$6,259	\$19.2000	C H 1%	
<b>Pancuronium bromide</b>					
Inj 2 mg per ml, 2 ml				H 1%	
<b>Penicillamine</b>					
Tab 125 mg	14,536	\$9,773	\$0.6723	C H 1%	
Tab 250 mg	51,883	\$57,134	\$1.1012	C H 1%	
<b>Suxamethonium chloride</b>					
Inj 50 mg per ml, 2 ml				H 1%	There may be a preference for a pre-filled syringe
<b>Tenoxicam</b>					
Inj 20 mg	1	\$10	\$9.9500	C H 1%	

**Nervous System**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Alfentanil</b>					
Inj 0.5 mg per ml, 2 ml ampoule				H 1%	
<b>Amantadine hydrochloride</b>					
Cap 100 mg	758,528	\$483,433	\$0.6373	C H 1%	
<b>Amitriptyline</b>					
Tab 10 mg	19,223,082	\$322,948	\$0.0168	C H 1%	
Tab 25 mg	7,989,633	\$134,226	\$0.0168	C H 1%	
Tab 50 mg	2,565,953	\$72,360	\$0.0282	C H 1%	
<b>Aprepitant</b>					
Cap 2 x 80 mg and 1 x 125 mg	23,646	\$788,200	\$33.3333	C H 1%	Special Authority restrictions may apply
<b>Bethahistine dihydrochloride</b>					
Tab 16 mg	2,967,917	\$174,899	\$0.0589	C H 1%	
<b>Bupivacaine hydrochloride</b>					
Inj 2.5 mg per ml, 100 ml bag				H 1%	
Inj 5 mg per ml, 4 ml				H 1%	
<b>Bupivacaine hydrochloride with adrenaline</b>					
Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml sterile pack				H 1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Bupivacaine hydrochloride with adrenaline</b>					
Inj 5 mg per ml with adrenaline 1:200,000, 20 ml sterile pack				H 1%	
<b>Buprenorphine with Naloxone</b>					
Tab sublingual 2 mg with naloxone 0.5 mg	253,760	\$520,207	\$2.0500 #	C H 1%	Special Authority restrictions may apply
Tab sublingual 8 mg with naloxone 2 mg	290,040	\$1,719,523	\$5.9286 #	C H 1%	Special Authority restrictions may apply
<b>Bupropion hydrochloride</b>					
Tab modified-release 150 mg	2,147,912	\$355,845	\$0.1657	C H 1%	
<b>Dexmedetomidine hydrochloride</b>					
Inj 100 mcg per ml, 2 ml vial				H 1%	
<b>Diazepam</b>					
Tab 2 mg	2,858,314	\$65,398	\$0.0229	C H 1%	
Tab 5 mg	4,278,085	\$117,305	\$0.0274	C H 1%	
<b>Donepezil hydrochloride</b>					
Tab 5 mg	1,173,411	\$71,449	\$0.0609	C H 1%	
Tab 10 mg	1,076,455	\$125,708	\$0.1168	C H 1%	
<b>Escitalopram</b>					
Tab 10 mg	6,665,749	\$333,287	\$0.0500	C H 1%	
Tab 20 mg	2,619,080	\$224,481	\$0.0857	C H 1%	
<b>Fentanyl</b>					
Patch 12.5 mcg per hour	172,680	\$100,845	\$0.5840	C H 1%	
Patches 100 mcg per hour				C H 1%	
Patches 25 mcg per hour	142,392	\$104,231	\$0.7320	C H 1%	
Patches 50 mcg per hour	60,485	\$80,324	\$1.3280	C H 1%	
Patches 75 mcg per hour	19,091	\$35,051	\$1.8360	C H 1%	
<b>Haloperidol decanoate</b>					
Inj 100 mg per ml, 1 ml ampoule				H 1%	
Inj 50 mg per ml, 1 ml ampoule				H 1%	
<b>Levodopa with Carbidopa</b>					
Tab 100 mg with carbidopa 25 mg	7,548,917	\$1,509,783	\$0.2000	C H 1%	
Tab 250 mg with carbidopa 25 mg	355,267	\$142,107	\$0.4000	C H 1%	
Tab long-acting 200 mg with carbidopa 50 mg	2,053,565	\$975,443	\$0.4750	C H 1%	Pharmacokinetic data required
<b>Levomepromazine</b>					
Tab 100 mg	94,372	\$41,486	\$0.4396	C H 1%	
Tab 25 mg	523,512	\$88,631	\$0.1693	C H 1%	
<b>Lidocaine [lignocaine] hydrochloride</b>					
Lidocaine [lignocaine] hydrochloride - Spray - 10 mg dose per spray				H 1%	
Oral [viscous] soln 2%	1,109,199	\$305,030	\$0.2750	C H 1%	
<b>Lidocaine [lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride</b>					
Soln 4% with adrenaline 0.1 % and tetracaine hydrochloride 0.5%, 5 ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<b>Lithium carbonate</b>					
Cap 250 mg	1,955,948	\$184,250	\$0.0942	C H 1%	
<b>Methadone hydrochloride</b>					
Inj 10 mg per ml, 1 ml	28,524	\$173,996	\$6.1000	C H 1%	
<b>Metoclopramide hydrochloride</b>					
Inj 5 mg per ml, 2 ml ampoule	216,568	\$97,456	\$0.4500	C H 1%	
Tab 10 mg	6,083,318	\$110,716	\$0.0182	C H 1%	
<b>Morphine sulphate</b>					
Inj 1 mg per ml, 100 ml bag				H 1%	
Inj 1 mg per ml, 10 ml syringe				H 1%	
Inj 1 mg per ml, 50 ml syringe				H 1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
<b>Morphine sulphate</b>					
<u>Inj 5 mg per ml, 1 ml ampoule</u>	75,196	\$187,689	\$2.4960	C H 1%	
<u>Inj 10 mg per ml 1 ml ampoule</u>	195,698	\$355,779	\$1.8180	C H 1%	
<u>Inj 15 mg per ml, 1 ml ampoule</u>	3,548	\$6,933	\$1.9540	C H 1%	
<u>Inj 30 mg per ml, 1 ml ampoule</u>	65,849	\$163,701	\$2.4860	C H 1%	
<u>Tab immediate release 10 mg</u>	3,021,906	\$846,134	\$0.2800	C H 1%	
<u>Tab immediate release 20 mg</u>	810,406	\$447,344	\$0.5520	C H 1%	
<b>Naltrexone hydrochloride</b>					
<u>Tab 50 mg</u>	141,083	\$357,409	\$2.5333	C H 1%	Special Authority restrictions may apply
<b>Nitrazepam</b>					
<u>Tab 5 mg</u>	481,676	\$25,143	\$0.0522	C H 1%	
<b>Olanzapine</b>					
<u>Orodispersible tab 5 mg</u>	311,443	\$19,465	\$0.0625	C H 1%	
<u>Orodispersible tab 10 mg</u>	511,874	\$55,758	\$0.1089	C H 1%	
<u>Tab 2.5 mg</u>	1,341,279	\$35,933	\$0.0268	C H 1%	
<u>Tab 5 mg</u>	2,096,386	\$123,540	\$0.0589	C H 1%	
<u>Tab 10 mg</u>	2,807,496	\$255,679	\$0.0911	C H 1%	
<b>Ondansetron</b>					
<u>Tab disp 4 mg</u>	1,687,012	\$168,701	\$0.1000	C H 1%	
<u>Tab disp 8 mg</u>	770,485	\$115,573	\$0.1500	C H 1%	
<b>Oxazepam</b>					
<u>Tab 10 mg</u>	778,537	\$48,036	\$0.0617	C H 1%	
<u>Tab 15 mg</u>	270,348	\$23,061	\$0.0853	C H 1%	
<b>Paracetamol</b>					
<u>Tab 500 mg</u>				H 1%	Preference for a pack size smaller than 100
<u>Tab soluble 500 mg</u>				H 1%	
<u>Inj 10 mg per ml, 50 ml</u>				H 1%	
<u>Inj 10 mg per ml, 100 ml</u>				H 1%	
<u>Oral liq 120 mg per 5 ml</u>	74,240,168	\$308,097	\$0.0042	C H 20%	Preference may be given to products which include a measuring device
<u>Oral liq 250 mg per 5 ml</u>	234,525,284	\$1,020,185	\$0.0044	C H 20%	Preference may be given to products which include a measuring device
<u>Tab 500 mg</u>	363,982,616	\$3,082,933	\$0.0085	C	
<b>Paracetamol with codeine</b>					
<u>Tab paracetamol 500 mg with codeine phosphate 8 mg</u>	49,107,852	\$1,034,211	\$0.0211	C H 1%	
<b>Pethidine hydrochloride</b>					
<u>Inj 50 mg per ml, 1 ml</u>	5,655	\$6,232	\$1.1020	C H 1%	
<u>Inj 50 mg per ml, 2 ml</u>	22,517	\$26,255	\$1.1660	C H 1%	
<b>Primidone</b>					
<u>Tab 25 mg</u>				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<u>Tab 50 mg</u>				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<b>Prochlorperazine</b>					
<u>Tab 5 mg</u>	3,636,475	\$70,911	\$0.0195	C H 1%	
<b>Quetiapine</b>					
<u>Tab 100 mg</u>	3,546,298	\$165,506	\$0.0467	C H 1%	
<u>Tab 200 mg</u>	1,314,872	\$105,190	\$0.0800	C H 1%	
<u>Tab 25 mg</u>	17,318,246	\$404,035	\$0.0233	C H 1%	Preference for scored tablet
<u>Tab 300 mg</u>	423,096	\$56,411	\$0.1333	C H 1%	
<b>Remifentanil hydrochloride</b>					
<u>Inj 1 mg</u>				H 1%	
<u>Inj 2 mg</u>				H 1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Risperidone</b>					
Inj 25 mg per 2 ml	7,137	\$970,489	\$135.9800	C H 1%	Depot injection. Special Authority restrictions may apply
Inj 37.5 mg per 2 ml	9,709	\$1,735,095	\$178.7100	C H 1%	Depot injection. Special Authority restrictions may apply
Inj 50 mg per 2 ml	12,735	\$2,770,627	\$217.5600	C H 1%	Depot injection. Special Authority restrictions may apply
<u>Oral liquid 1 mg per ml</u>	256,298	\$83,297	\$0.3250	C H 1%	
<u>Tab 0.5 mg</u>	2,526,765	\$80,023	\$0.0317	C H 1%	
<u>Tab 1 mg</u>	2,036,387	\$71,274	\$0.0350	C H 1%	
<u>Tab 2 mg</u>	975,430	\$38,042	\$0.0390	C H 1%	
<u>Tab 3 mg</u>	439,230	\$18,667	\$0.0425	C H 1%	
<u>Tab 4 mg</u>	220,037	\$12,835	\$0.0583	C H 1%	
<b>Rizatriptan</b>					
<u>Tab orodispersible 10 mg</u>	1,227,676	\$331,473	\$0.2700	C H 1%	
<b>Ropivacaine hydrochloride</b>					
Inj 2 mg per ml, 10 ml				H 1%	
Inj 2 mg per ml, 20 ml				H 1%	
Inj 2 mg per ml, 100 ml				H 1%	
Inj 2 mg per ml, 200 ml				H 1%	
Inj 7.5 mg per ml, 10 ml				H 1%	
Inj 7.5 mg per ml, 20 ml				H 1%	
Inj 10 mg per ml, 10 ml				H 1%	
Inj 10 mg per ml, 20 ml				H 1%	
<b>Sumatriptan</b>					
Nasal spray				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. May be subject to Special Authority restrictions
<b>Temazepam</b>					
<u>Tab 10 mg</u>	3,442,395	\$174,874	\$0.0508	C H 1%	
<b>Tramadol hydrochloride</b>					
<u>Cap 50 mg</u>	32,881,519	\$822,038	\$0.0250	C H 1%	
Inj 50 mg per ml, 1 ml				H 1%	
Inj 50 mg per ml, 2 ml				H 1%	
<u>Tab sustained release 100 mg</u>	4,119,516	\$411,952	\$0.1000	C H 1%	
<u>Tab sustained release 150 mg</u>	408,925	\$61,339	\$0.1500	C H 1%	
<u>Tab sustained release 200 mg</u>	301,307	\$60,261	\$0.2000	C H 1%	
<b>Trimipramine maleate</b>					
Cap 25 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule
Cap 50 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule
<b>Zolmitriptan</b>					
Nasal Spray				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. May be subject to Special Authority restrictions

**Oncology Agents and Immunosuppressants**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Bicalutamide</b>					
<u>Tab 50 mg</u>	405,107	\$70,894	\$0.1750	C H 1%	
<b>Calcium folinate</b>					
<u>Inj 50 mg</u>				PCT C H 1%	
<u>Inj 100 mg</u>				PCT H 1%	
<u>Inj 300 mg</u>				PCT H 1%	
<u>Inj 1 g</u>				PCT H 1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Oncology Agents and Immunosuppressants**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Docetaxel</b>					
<u>Inj 20 mg</u>				PCT H 1%	Preference for products where stability data >48 hours post-compounding
<u>Inj 80 mg</u>				PCT H 1%	Preference for products where stability data >48 hours post-compounding
<b>Exemestane</b>					
<u>Tab 25 mg</u>	238,130	\$115,095	\$0.4833	C H 1%	
<b>Gemcitabine hydrochloride</b>					
<u>Inj 200 mg</u>				PCT H 1%	Preference for products where stability data >48 hours post-compounding
<u>Inj 1 g</u>				PCT H 1%	Preference for products where stability data >48 hours post-compounding
<b>Imatinib mesilate</b>					
<u>Cap 400 mg</u>	36,248	\$722,302	\$19.9267 #	C H 1%	For non-GIST indications only
<u>Cap 100 mg</u>	282,428	\$1,406,963	\$4.9817 #	C H 1%	For non-GIST indications only
<b>Methotrexate</b>					
<u>Inj 100 mg per ml, 10 ml</u>				PCT C H 1%	Preference for products where stability data >48 hours post-compounding
<u>Inj 100 mg per ml, 50 ml</u>				PCT C H 1%	Preference for products where stability data >48 hours post-compounding
<b>Octreotide (somatostatin analogue)</b>					
<u>Inj 50 mcg per ml, 1 ml</u>	3,472	\$9,374	\$2.7000	C H 1%	
<u>Inj 100 mcg per ml, 1 ml</u>	3,031	\$13,579	\$4.4800	C H 1%	
<u>Inj 500 mcg per ml, 1 ml</u>	1,717	\$30,700	\$17.8800	C H 1%	
<b>Paclitaxel</b>					
<u>Inj 30 mg</u>				PCT H 1%	Preference for products where stability data >48 hours post-compounding
<u>Inj 100 mg</u>				PCT H 1%	Preference for products where stability data >48 hours post-compounding
<u>Inj 150 mg</u>				PCT H 1%	Preference for products where stability data >48 hours post-compounding
<u>Inj 300 mg</u>				PCT H 1%	Preference for products where stability data >48 hours post-compounding
<u>Inj 600 mg</u>				PCT H 1%	Preference for products where stability data >48 hours post-compounding

**Respiratory System and Allergies**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Aminophylline</b>					
<u>Inj 25 mg per ml, 10 ml</u>	2,500	\$59,125	\$23.6500	C H 1%	
<b>Cetirizine hydrochloride</b>					
<u>Oral liq 1 mg per ml</u>	12,140,515	\$181,501	\$0.0150	C H 1%	
<b>Ipratropium Bromide</b>					
<u>Aqueous nasal spray, 0.03%</u>	671,955	\$176,946	\$0.2633	C H 1%	

**Sensory Organs**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Acetazolamide</b>					
<u>Inj 500 mg</u>				H 1%	
<u>Tab 250 mg</u>	535,844	\$91,254	\$0.1703	C H 1%	
<b>Apraclonidine</b>					
<u>Eye drops 0.5%</u>			\$3.9540	C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<b>Atropine sulphate</b>					
<u>Eye drops 1%</u>	107,355	\$124,245	\$1.1573	C H 1%	

sole supply



**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Sensory Organs**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
<b>Betaxolol hydrochloride</b>					
<u>Eye drops 0.25%</u>	21,355	\$50,398	\$2.3600	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market
<u>Eye drops 0.5%</u>	6,340	\$9,510	\$1.5000	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market
<b>Brimonidine tartrate</b>					
<u>Eye Drops 0.15% - 0.2%</u>	191,515	\$165,469	\$0.8640	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market
<b>Brimonidine Tartrate with Timolol Maleate</b>					
Eye drops 0.2% with timolol maleate 0.5%	224,810	\$831,797	\$3.7000 #	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Unit subsidy expressed as "per ml"
<b>Ciprofloxacin (current access)</b>					
Eye Drops 0.3%	92,955	\$231,086	\$2.4860	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access
<b>Ciprofloxacin (widened access)</b>					
Eye drops 0.3%				C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access
<b>Ciprofloxacin with Hydrocortisone</b>					
Ear drops 0.2% with hydrocortisone 1%				H 1%	
<b>Cyclopentolate hydrochloride</b>					
<u>Eye drops 1%</u>	66,105	\$38,605	\$0.5840	C H 1%	
<b>Dexamethasone</b>					
<u>Eye drops 0.1 %</u>	130,640	\$117,576	\$0.9000	C H 1%	
<u>Eye oint 0.1%</u>	20,073	\$33,607	\$1.6743	C H 1%	
<b>Dexamethasone with framycetin and gramicidin</b>					
Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml	502,152	\$282,461	\$0.5625	C H 1%	
<b>Dexamethasone with neomycin sulphate and polymyxin B sulphate</b>					
<u>Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml</u>	102,780	\$92,502	\$0.9000	C H 1%	
<u>Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g</u>	34,073	\$52,472	\$1.5400	C H 1%	
<b>Dexamethasone with tobramycin</b>					
Eye drops 0.1% with tobramycin 0.3%			\$2.5280	C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<b>Diclofenac sodium</b>					
<u>Eye drops 1 mg per ml, 5 ml</u>	113,465	\$313,163	\$2.7600	C H 1%	
<b>Lodoxamide</b>					
<u>Eye drops 0.1%</u>	301,830	\$262,894	\$0.8710	C H 1%	
<b>Loteprednol etabonate</b>					
Eye drop 0.5% (pack size less than or equal to 5 ml)				C H 1%	Not currently listed in the Pharmaceutical Schedule.
<b>Naphazoline hydrochloride</b>					
<u>Eye drops 0.1%</u>	104,175	\$28,822	\$0.2767	C H 1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Sensory Organs**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Paraffin liquid with wool fat liquid</b>						
<u>Eye oint 3% with wool fat liq 3%</u>	83,563	\$86,666	\$1.0371	C H	1%	
<b>Pilocarpine hydrochloride</b>						
<u>Eye drops 1%</u>	16,395	\$4,656	\$0.2840	C H	1%	
<u>Eye drops 2%</u>	40,260	\$14,360	\$0.3567	C H	1%	
<u>Eye drops 4%</u>	28,350	\$15,101	\$0.5327	C H	1%	
<b>Prednisolone acetate</b>						
<u>Eye drops 0.12%</u>	50,130	\$45,117	\$0.9000	C H	1%	
<b>Timolol maleate</b>						
<u>Eye drops 0.25%</u>	147,265	\$42,707	\$0.2900	C H	1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market
<u>Eye drops 0.5%</u>	142,220	\$41,244	\$0.2900	C H	1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market
<b>Tobramycin</b>						
<u>Eye drops 0.3%</u>	2,575	\$5,912	\$2.2960	C H	1%	
<u>Eye oint 0.3%</u>	1,554	\$4,640	\$2.9857	C H	1%	
<b>Tropicamide</b>						
<u>Eye drops 0.5%</u>	1,080	\$515	\$0.4767	C H	1%	Single dose presentation would not be a DV Pharmaceutical
<u>Eye drops 1%</u>	5,430	\$3,135	\$0.5773	C H	1%	Single dose presentation would not be a DV Pharmaceutical

**Various**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Chlorhexidine with ethanol</b>						
Soln 2% with ethanol 70%, non-staining (pink) 100 ml					H 1%	
Soln 2% with ethanol 70%, non-staining pink (pack size less than 50 ml)					H 1%	
Soln 2% with ethanol 70%, staining (red) 100 ml					H 1%	
Soln 2% with ethanol 70%, staining red (pack size less than 50 ml)					H 1%	
<b>Povidone Iodine</b>						
Oint 10%			#		H 1%	